BioNTech has obtained $110 million in new financing to strengthen Africa’s first mRNA vaccine manufacturing facility in Rwanda, marking a major step toward vaccine self-sufficiency on the continent.
German biotechnology company BioNTech has received $110 million in funding from the European Investment Bank (EIB) and the European Commission to support its mRNA vaccine production site in Kigali, Rwanda. The facility, which officially opened in 2023, represents a cornerstone in efforts to build local vaccine production capacity in Africa.
The Rwandan plant is designed to produce vaccines for COVID-19 as well as other major infectious diseases including malaria, tuberculosis, HIV, and mpox. Once fully operational, the facility aims to supply vaccines to several African countries, helping reduce the continent’s dependence on imports.
Currently, Africa produces only about 1% of the vaccines it consumes, leaving it vulnerable to supply shortages and global market fluctuations. BioNTech’s Rwanda project is therefore seen as a strategic move toward regional health security and biotechnology innovation.
The new financing package will help expand the site’s infrastructure and enable large-scale vaccine manufacturing using modular mRNA technology. This funding is also part of a broader European initiative to support sustainable health manufacturing and innovation in Africa.
With this investment, Rwanda strengthens its position as a biotech hub for Africa, while BioNTech advances its mission to ensure equitable vaccine access across the globe.
